C-myc gene amplification in different stages of oesophageal squamous cell carcinoma: prognostic value in relation to treatment modality

Anticancer Res. 2003 Mar-Apr;23(2B):1489-93.

Abstract

Background: The proto-oncogene c-myc is known to be involved in the regulation of proliferation, apoptosis and cell differentiation.

Materials and methods: Amplification of c-myc was determined by means of differential PCR in 77 surgically treated stage I or II oesophageal squamous cell carcinomas (SCC) as well as in 43 locally advanced SCC (cT3-4 cN0-1 cM0) treated by radiochemotherapy and facultatively by surgery. The findings were correlated to overall survival and to response to radiochemotherapy.

Results: C-myc gene amplification was present in 8 out of 77 surgically treated SCC (10.4%) and in 13 out of 43 multimodally treated SCC (30.2%). Among the surgically treated tumours, the presence of c-myc amplification was correlated with high proliferative activity (p = 0.0399) but not with overall survival. Among the multimodally treated SCC, c-myc amplification tended to be correlated with response to chemotherapy and response to radiochemotherapy (not significant) whereas no impact on overall survival was found.

Conclusion: Amplification of c-myc is found more frequently in advanced stages of oesophageal SCC than in early stages. C-myc amplification, however, does not influence the overall survival of oesophageal SCC patients treated either by surgery alone or by multimodal therapy.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carcinoma, Squamous Cell / drug therapy
  • Carcinoma, Squamous Cell / genetics*
  • Carcinoma, Squamous Cell / mortality
  • Carcinoma, Squamous Cell / pathology
  • Carcinoma, Squamous Cell / radiotherapy
  • Carcinoma, Squamous Cell / surgery
  • Cell Division
  • Cisplatin / administration & dosage
  • Clinical Trials as Topic
  • Combined Modality Therapy
  • Disease Progression
  • Esophageal Neoplasms / drug therapy
  • Esophageal Neoplasms / genetics*
  • Esophageal Neoplasms / mortality
  • Esophageal Neoplasms / pathology
  • Esophageal Neoplasms / radiotherapy
  • Esophageal Neoplasms / surgery
  • Esophagectomy
  • Etoposide / administration & dosage
  • Female
  • Fluorouracil / administration & dosage
  • Follow-Up Studies
  • Gene Amplification*
  • Genes, myc*
  • Humans
  • Leucovorin / administration & dosage
  • Male
  • Middle Aged
  • Multicenter Studies as Topic
  • Polymerase Chain Reaction
  • Prognosis
  • Prospective Studies
  • Proto-Oncogene Mas
  • Remission Induction
  • Survival Analysis
  • Treatment Outcome

Substances

  • MAS1 protein, human
  • Proto-Oncogene Mas
  • Etoposide
  • Cisplatin
  • Leucovorin
  • Fluorouracil

Supplementary concepts

  • FLEP regimen